TRIL Trillium Therapeutics Inc.

Trillium Therapeutics Inc is an immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc and CD200 monoclonal antibody targets immuno regulatory pathways that tumor cells exploit to evade the host immune system.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CT:TRIL.

$10.86  +0.09 (0.79%)
As of 06/25/2021 09:45:19 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  02/15/2013
Outstanding shares:  103,137,175
Average volume:  1,061,413
Market cap:   $1,060,250,159
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      40-F
CUSIP:    89620X506
Valuation   (See tab for details)
PE ratio:   22.05
PB ratio:   125.23
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy